baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out Genmab AS/ DE000SU0ZPG5 /

5/29/2024 9:49:20 AM	Chg.+0.12	Bid5:04:36 PM	Ask5:04:36 PM	Underlying	Strike price	Expiration date	Option type
1.29EUR	+10.26%	1.28 Bid Size: 3,000	1.33 Ask Size: 3,000	-	2,390.0104 DKK	12/31/2078	Put

GlobeNewswire 2:00 PM BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 5/21 Genmab Completes Acquisition of ProfoundBio

GlobeNewswire 5/21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 5/17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

GlobeNewswire 5/14 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...

GlobeNewswire 5/14 Immatics Announces First Quarter 2024 Financial Results and Business Update

GlobeNewswire 5/6 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 5/2 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 4/30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...

GlobeNewswire 4/22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 4/7 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

GlobeNewswire 4/3 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

GlobeNewswire 3/20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 3/20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire 3/11 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...

GlobeNewswire 3/7 BioNTech Announces Planned Retirement of Sean Marett

GlobeNewswire 3/6 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...

GlobeNewswire 3/4 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...

GlobeNewswire 2/14 Genmab Announces Initiation of Share Buy-Back Program

GlobeNewswire 2/14 Genmab Publishes 2023 Annual Report

GlobeNewswire 2/8 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...

GlobeNewswire 1/31 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...

GlobeNewswire 1/22 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...

GlobeNewswire 1/9 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

Soc. Generale Knock-Out Genmab AS/ DE000SU0ZPG5 /

If you wish to receive reply to your feedback, please provide your email address.